Sun Phar­ma takes aim at a crowd­ed mar­ket with an­oth­er IL-23 pso­ri­a­sis drug from Mer­ck

In the last minute, late-stage race to the mar­ket with a new round of pso­ri­a­sis drugs, In­dia’s Sun Phar­ma­ceu­ti­cals is mak­ing its own bid with a new drug called tildrak­izum­ab. In-li­censed from Mer­ck, which agreed to han­dle the late-stage work for Sun for the for­mer MK-3222, it’s an­oth­er IL-23 drug, like J&J’s guselkum­ab.

But it didn’t per­form as well as the J&J drug in late-stage de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER